Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRANSFORM-2
jRCT2011210016Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, open-label trial in myelofibrosis (MF) comparing Arm A: Navitoclax + Ruxolitinib with Placebo for Navitoclax + Ruxolitinib (2 arms). Primary endpoint: Spleen volume reduction at week 24. Started Aug 2021; status: active, not recruiting.
02
Drugs
navitoclaxruxolitinib
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on jRCT2011210016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2011210016.